ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

NCI awards $7.3 Million for Studies In Cancer communications

October 15, 1993

LeMaistre Blasts “Death Merchants’ In tobacco Industry

May 5, 1989

Growing Number Of New Research Ideas Create NCI Dilemma; How to Fund Them With A Flat Budget

October 1, 1982

In Brief: David Sundial Named Health Director Of Senate Labor & Human Resources Committee’s HHS Office

September 20, 1985

NIH establishes new clinical science awards to eventually replace General Clinical Research Centers.

October 21, 2005

Obituaries: Karen Johnson of NCI; Merrill Egorin of UPCI

September 17, 2010